Using Precision to Bring Innovation to Mental Health Therapeutic Development: Hugh Marston, Head of Global CNS Diseases

Over the last decade Boehringer Ingelheim has grown its neuroscience research portfolio to incorporate mental health in combination with neurodegenerative disease. This initiative was made deliberately to take advantage of shifts in thinking, such as RDoC. In that time Boehringer Ingelheim has developed a portfolio of programs that aim to be iteratively more “precise.” This symposium will highlight examples of how Boehringer Ingelheim has shifted its thinking about drug discovery in the mental health space, focusing on the patient rather than the model, and to share some of its successes and failures. Significant challenges remain even if basic “drug discovery” is effective. Issues such “clinical trial effects,” stratification versus biomarkers, and validation of end points are near term. Other hurdles such as easy acceptance of new approaches in clinical delivery may exist in the midterm. This symposium seeks to foster conversations that will bring together academic, clinical, and industry perspectives to explore avenues for collaboration to improve the lives of those living with mental health conditions.

opnMe.com - How Boehringer Ingelheim Is Fostering Academic Iinnovation Using Open Innovation: Florian Montel, Head of Open Science

Agenda:
12:45 – Arrival
1:00 – 1:45 – Boehringer Ingelheim Presentation
1:45 – 2:00 – Q&A
2:00 – 2:20 – opnMe Presentation
2:20 – 2:30 – Q&A
2:30 – 3:00 - Networking

For questions or help with registration, please contact Ben Stang, ben.stang@yale.edu.